Is Real-world Evidence (RWE) the new gold standard for data generation? Our latest whitepaper investigates how RWE is transforming the pharma industry, offering a future-proof, cost-effective approach to drug approval and market access. While Randomised Clinical Trials (RCTs) have long been the gold standard, their limitations—high costs, lengthy timelines, and narrow patient criteria—have driven the need for complementary methods like RWE.